|
ICOS' and Lilly's judgment as of the date of this release. ICOS and Lilly undertake no obligation to publicly update any forward-looking statements. (2) IMS National Prescription Audit Plus 7(TM), April 2004.(3) A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil. Alexander Von Keitz, MD; Jacob Rajfer, MD; Scott Segal, MD; Aileen Murphy, MPH: Jonathan Denne, PhD; Timothy Costigan, PhD; Daniel Lockhart, PhD; Charles Beasley, MD; Jeffrey T. Emmick, MD, PhD. European Urology (Vol. 45, issue 4) -Selected financial data follows- Lilly ICOS LLC Condensed Consolidated Statements of Operations (in thousands) (unaudited) Three Months Ended March 31, ------------------------ 2004 2003 ----------- ----------- Revenue: Product sales, net $75,017 $16,615 Royalties 6,652 975 ----------- ----------- Total revenue 81,669 17,590 ----------- ----------- Expenses: Cost of sales 6,573 1,604 Selling, general and administrative 195,053 42,
cialis 2003 release by reduced clinical activity associated with seeking FDA approval for Cialis.About Lilly ICOS LLCLilly ICOS LLC cialis 2003 release, a 50 50 joint venture between ICOS Corporation and Eli Lilly and Company cialis 2003 release, is marketing Cialis for the treatment of erectile dysfunction in North America and Europe.Eli Lilly and Company cialis 2003 release, a leading innovation-driven corporation cialis 2003 release, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis cialis 2003 release, Indiana cialis 2003 release, Lilly provides answers -- through medicines and information cialis 2003 release.
cialis 2003 release -- for some of the world's most urgent medical needs.ICOS Corporation cialis 2003 release, a biotechnology company cialis 2003 release, is dedicated to bringing innovative therapeutics to patients. Headquartered in Bothell cialis 2003 release, Washington cialis 2003 release, ICOS is marketing its first product cialis 2003 release, Cialis® (tadalafil) cialis 2003 release, for the treatment of erectile dysfunction. ICOS is working to develop treatments for serious unmet medical conditions such as chronic obstructive pulmonary disease cialis 2003 release, cancer and inflammatory diseases.Except for historical information contained herein cialis 2003 release, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations cialis 2003 release, estimates and projections about the industry cialis 2003 release, management beliefs and certain assumptions made by the management of ICOS and Lilly. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties cialis 2003 release, including economic cialis 2003 release, competitive cialis 2003 release, governmental cialis 2003 release, technological cialis 2003 release, legal and other factors discussed in the two companies' respective filings with the Securities and Exchange Commission cialis 2003 release, which may affect the business and prospects of the two companies and Lilly ICOS. Results and the timing and outcome of events may differ materially from those expressed or implied by the forward-looking statem.
cialis 2003 release are based on current expectations cialis 2003 release, estimates and projections about the industry cialis 2003 release, management beliefs and certain assumptions made by the management of ICOS and Lilly. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties cialis 2003 release, including economic cialis 2003 release, competitive cialis 2003 release, governmental cialis 2003 release, technological cialis 2003 release, legal and other factors discussed in the two companies' respective filings with the Securities and Exchange Commission cialis 2003 release, which may affect the business and prospects of the two companies and Lilly ICOS. Results and the timing and outcome of events may differ materially from those expressed or implied by the forward-looking stateme.
cialis 2003 release 
cialis 2003 release | Free ringtones
| Cheapest ultram
| Free ringtones for verizon customers
| Free ringtones for samsung r225m
| Free polyphonic ringtones order
| cialis 2003 release
Rst year on the market, 2003 worldwide net product sales of Cialis totalled $203.3 million, of which $129.8 million represent sales in Lilly ICOS joint venture territories and $73.5 million represent sales in Lilly-only territories. Total Lilly ICOS revenue was $144.5 million, including $14.7 million in royalties on Cialis sales reported by Lilly. Cialis has successfully captured a significant share of unit (tablet) sales in Europe among the three PDE5 inhibitors Cialis, Viagra(R) (sildenafil) and Levitra(R) (vardenafil) . For November 2003, based on pharmacy purchases from wholesalers(2), Cialis had a 35% share in France, 30% in Germany, 27% in Italy and 16% in both Spain and the United Kingdom. And, through November 2003, those markets continue to grow at healthy rates(2) -- ranging from 22% in Italy up to 40% in Germany. Cost of sales totalled $12.5 million in 2003, including royalties payable by Lilly ICOS equal to five percent of its net product sales. Selling, general and adminis
|
